DBV Technologies stock

DBV · Euronext Paris · EUR

Compare DBV Technologies
€1.66Change from previous close: −6.64%Absolute change: −€0.12

Close · November 20, 2026

Price history

−33.01% over the period

1 year: from €2.47 (November 20, 2025) to €1.66 (November 20, 2026), −33.01%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 20, 2026€1.66
October 30, 2026€1.70
September 30, 2026€2.07
August 31, 2026€2.37
July 31, 2026€2.35
June 30, 2026€2.82
May 29, 2026€3.36
April 30, 2026€3.63
March 31, 2026€3.63
February 27, 2026€3.59
January 30, 2026€3.81
December 31, 2025€3.38
November 28, 2025€2.29
November 20, 2025€2.47

At a glance

  • The company

    Clinical-stage biopharmaceutical company developing epicutaneous immunotherapy products for food allergies and related conditions

  • Latest results

    Quarter to September 30, 2026 · EPS -$0.03 (estimate -$0.02)

TickerLandia's take on DBV Technologies

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low€1.53
52-wk high€4.50

−63.16% from the 52-week high

Analysts · 4 analysts

Average target€3.60+117.13% vs. price

Buy 3 · Hold 0 · Sell 1 · Buy

TickerLandia Fingerprint: DBV Technologies

Compared with similar companies: very weak momentum, very low earnings stability, and very low growth.

Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 1,160 European stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

DBV Technologies is cheaper than similar companies

DBV Technologies's Price/book: 3.94, −12% against the median of a group of 10 similar companies (4.45).

Compared with 11 similar companies

DBV Technologies's metrics compared with similar companies
MetricDBV TechnologiesPosition in the groupBand
Operating margin-5,577.0%Low
ROE-205.9%Low
Debt/equity0.05Middle
Price/book3.94Middle
Net margin0.0%Middle

Grey band: the middle half of the group; tick: the median; dot: DBV Technologies. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

$1.6M

Latest quarter · Q3 2026

Net income

-$64.5M

Latest quarter · Q3 2026

Quarterly net margin

-4,031.3%

Latest quarter · Q3 2026

Numbers and valuation

Full valuation
Market cap
€520.95M
EPS
-€0.52
Volume
1.04M
Daily trading
€2.33M
Dividend yield
0.00%

How DBV Technologies is changing

All results
  • Revenue fell 13.0% a year on average over the last 5 years

  • Operating margin fell from −1,994.9% to −2,609.2%

  • Shares outstanding up 158.0% in 5 years

Returns

DBV Technologies returns

€1,000 invested in DBV Technologies 5 years ago, on November 22, 2021, would be worth €312 today: −68.82% in total, −20.82% per year. This is the price return only: dividends are excluded.

PeriodDBV TechnologiesCAC 40€1,000 becomes
1 month−3.10%+1.14%€969
6 months−48.73%−2.34%€513
Year to date−50.95%−2.72%€491
1 year−33.01%−0.67%€670
3 years+1.10%+9.39%€1,011
5 years−68.82%+11.58%€312
10 years−97.56%+75.02%€24

Over the last 6 months it has done better than 0% of the stocks in the Healthcare sector.

Price only, without dividends. Calculate your investment

The chart in detail

DBV Technologies: technical analysis

DBV Technologies is in a downtrend: the price is below its 50- and 200-session moving averages, and the 200-session average is falling. The price is 98.0% below its all-time closing high (€83.51, October 12, 2017).

Trend
Downward
RSI (14 sessions)
40
Between 30 and 70
vs 200-session average
−40.20%

Support and resistance

Price areas where DBV Technologies has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. Resistance€2.63+58.38%2 touches, last on August 19, 2026
  2. Resistance€2.53+52.29%2 touches, last on June 30, 2026
  3. Resistance€2.22+33.84%3 touches, last on November 11, 2026
  4. Last price€1.66
  5. No support below: the price is near the lows of the year

Volatility and risk

Over the last year it has moved little with the CAC 40.

Beta (1 year) vs CAC 40
0.32
Volatility (60 sessions, annualised)
63.2%
Largest fall in the last year
−63.24%

Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

DBV Technologies: seasonality

Average monthly price change over 15 years

+6.7%Jan+1.0%Feb+4.0%Mar+7.0%Apr−2.0%May+0.7%Jun+4.5%Jul−2.5%Aug−1.1%Sep−6.6%Oct−0.2%Nov+3.8%Dec

Over the last 15 years, the strongest month for DBV Technologies has been April: +7.01% on average, positive in 8 years out of 15. The weakest has been October: −6.63% on average, positive in 4 years out of 15. November, the current month, has been positive in 7 years out of 14 (−0.24% on average).

Show chart data
MonthAverageMedianPositive years
January+6.69%−4.25%5 of 14
February+0.97%−1.50%6 of 14
March+4.01%+4.54%9 of 14
April+7.01%+0.14%8 of 15
May−1.96%−5.91%6 of 15
June+0.75%−0.96%6 of 15
July+4.48%+2.52%8 of 15
August−2.55%−1.85%7 of 15
September−1.10%−5.59%5 of 15
October−6.63%−12.61%4 of 15
November−0.24%−0.93%7 of 14
December+3.81%+6.33%9 of 14

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

DBV Technologies and its competitors

Viaskin Peanut, an epicutaneous immunotherapy product for peanut allergy, has completed a Phase 3 clinical trial, while Viaskin Milk, aimed at cow's milk protein allergy and eosinophilic esophagitis, is in Phase 1/2 trials. The company also runs earlier-stage research into celiac disease and develops the Viaskin technology platform, which is designed to potentially treat food allergy. Its collaboration with Nestlé Health Science covers MAG1C, a ready-to-use atopy patch test for diagnosing non-IgE mediated cow's milk protein allergy in infants and toddlers.

Headquarters
Châtillon, France
Employees
179
Founded
2002
Chief executive
Daniel Tassé
DBV Technologies and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
DBV TechnologiesDBV$572.52M-5,577.0%—−48.73%
GubraGUBRA$730.02M-73.1%—−22.24%
Pharming GroupPHARM$841.25M12.8%36.1−2.57%
InventivaIVA$890.8M-5,980.9%—−33.75%
PhilogenPHIL$905.96M79.1%3.67−5.63%
Basilea PharmaceuticaBSLN$1.07B24.2%18.1+35.06%

Same industry or related industries, similar size. Compare DBV Technologies with its competitors · Full profile